Background Comorbid type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) represent a major clinical burden, driven by overlapping metabolic and inflammatory mechanisms. Genetic factors are increasingly recognized as contributors to individual susceptibility, yet the specific variants influencing T2DM-associated CHD remain incompletely defined. Complement 5a receptor 2 (C5L2) serves as a receptor for acylation-stimulating protein (ASP) and C5a, regulating glucose uptake, triglyceride clearance, lipid metabolism, and immune signaling, and has been implicated in both pro- and anti-inflammatory pathways. This study investigates whether C5L2 polymorphisms are associated with T2DM-CHD and integrate with metabolic and inflammatory markers in the Han Chinese population from Xinjiang. Methods A hospital-based case-control study was conducted involving 951 adult participants (206 with T2DM and CHD, and 745 controls), who were genotyped for two single-nucleotide polymorphisms (SNPs), C5L2 rs2972607 and rs8112962, using improved multiplex ligation detection reaction methods. Clinical, hematologic, and biochemical traits were measured. Logistic regression assessed genotype–disease and genotype–phenotype links (sex-adjusted). MDR evaluated high-order gene–environment interactions using 10-fold cross-validation and balanced accuracy. Results rs2972607 was significantly associated with HDL-C, lymphocytes, platelet indices, AST/ALT, UCB, and 5′-NT; rs8112962 was associated with monocytes and HDL-C. Sex-stratified analyses confirmed associations between HDL-C and UCB in both sexes; platelet effects were stronger in females. In multivariable models, rs2972607 remained a modest but significant independent predictor (OR = 2.07; P = 0.007). MDR identified a statistical hub comprising rs2972607 + glucose + TyG + WBC + HDL -C (Training Bal.Acc.CV = 0.996; Testing Bal.Acc.CV = 0.606; CV consistency = 10 /10). These patterns align with C5L2's established roles in lipid/glucose handling and complement-driven inflammation Conclusions C5L2 polymorphisms, particularly rs2972607, are modest but consistent contributors to T2DM–associated CHD and integrate with lipid, platelet, and inflammatory markers, highlighting a potential role in immune–metabolic interplay. While our findings are observational and hypothesis-generating, they are biologically plausible and align with established C5L2 biology, suggesting that integrating C5L2 genotyping with biochemical profiling may refine individualized risk prediction and guide future mechanistic studies.
Liu et al. (2025) studied this question.